FATE vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 02, 2026

FATE

46.8
AI Score
VS
FATE Wins

CBIO

37.7
AI Score

Investment Advisor Scores

FATE

47score
Recommendation
HOLD

CBIO

38score
Recommendation
SELL

AI Analyst Insights

Detailed Metrics Comparison

Metric FATE CBIO Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 9.2% 0.0% FATE
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 46.8/100 37.7/100 FATE
Profit Margin 0.0% 0.0% Tie
Beta 1.00 1.00 Tie
AI Recommendation HOLD SELL FATE

Relative Price Performance (Last 90 Days)

FATE 1M: -17.8% · 3M: -34.7% CBIO 1M: +11.9% · 3M: -13.1%

Current Technical Phase

FATE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -9.5%), weak momentum, RSI 32

RSI (14): 31.7 · Price: $1.65

CBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 56

RSI (14): 55.6 · Price: $14.45

Fundamentals Snapshot

Metric FATE CBIO
Market Cap — —
Forward P/E -1.8 -5.3
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.1% 0.0%
Gross Margin -12.0% 1.0%
Operating Margin -15.0% -14.3%
EPS -1.09 -7.63
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, FATE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.